Reader Comments

DRUG THERAPY IN THE PROGRESSED CML PATIENT

by neil neil jakson jakson (2018-01-19)


The aim of this paper is to outline pharmacotherapy of the 'third-line management ofCML' (progressive disease course after sequential TKI drugs. Current management of CML with multi-TKI failure is reviewed. TKI (bosutinib, ponatinib, dasatinib, nilotinib) and non-TKI (omacetaxine mepussecinate,Dissertation writing services

 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185     •     Privacy